Literature DB >> 32918336

Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.

Ryan A Wilcox1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32918336     DOI: 10.1002/ajh.25985

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  JAK inhibition as a new treatment strategy for patients with COVID-19.

Authors:  Jin Huang; Chi Zhou; Jinniu Deng; Jianfeng Zhou
Journal:  Biochem Pharmacol       Date:  2022-07-03       Impact factor: 6.100

2.  Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.

Authors:  Philip S Boonstra; Asra Ahmed; Samuel A Merrill; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-01-28       Impact factor: 10.047

3.  Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?

Authors:  Sujoy Khan
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

Review 4.  Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.

Authors:  Vincenzo Lariccia; Simona Magi; Tiziano Serfilippi; Marwa Toujani; Santo Gratteri; Salvatore Amoroso
Journal:  J Clin Med       Date:  2020-12-12       Impact factor: 4.241

5.  Macrophage activation syndrome in rheumatic disease: Clinical characteristics and prognosis of 20 adult patients.

Authors:  So Hye Nam; Soo Min Ahn; Ji Seon Oh; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Yong-Gil Kim
Journal:  PLoS One       Date:  2022-05-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.